Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer
收藏NIAID Data Ecosystem2026-03-10 收录
官方服务：
资源简介：
The POLE mutations represent high somatic mutation loads in patients with colorectal cancer, especially in those with MMR proficient or MSS, therefore, tumors harbouring POLE mutations might be susceptible to immune checkpoint blockade. Based on these reasons, Investigator planned a phase II study of avelumab monotherapy in patients with previously treated, metastatic, MMR deficient (MSI-H) or POLE mutated colorectal cancer.
创建时间：
2017-05-15
